News

Breaking News

Vienna, Austria | FOR IMMEDIATE RELEASE October 6, 2026

Tridem Bioscience Enrolls First Patients in Phase Ib Clinical Study of its Lead Vaccine Candidate for Parkinson’s Disease

Advancing a differentiated active immunotherapy approach targeting alpha-synuclein in Parkinson’s disease; first human data confirm unique translational potential; pipeline expanded to Alzheimer’s disease, dermatology and ASCVD; company actively seeking pharmaceutical partnering

Vienna, Austria — Tridem Bioscience, a clinical-stage biopharmaceutical company pioneering active immunotherapy for neurodegeneration, inflammatory skin diseases, and atherosclerotic cardiovascular disease (ASCVD), today announced enrollment of the first patients in its Phase Ib clinical study of its lead vaccine candidate, TRB-001, in Parkinson’s disease. Tridem also reported encouraging data from its named-patient-use (NPU) program with TRB-001 and has completed recruitment for a small POC-type Phase I study with this candidate. Tridem Bioscience is actively seeking strategic co-development and licensing partnerships for its programs.

Publications

Conference Presentations

Press Releases

Consortium and Funding:

NEXGEN-PD is coordinated by Tridem Bioscience and has received €6 million in funding from the European Union’s Horizon Europe Framework Programme under grant agreement No 101080267. UK participants in NEXGEN-PD are supported by UKRI grant number 10064393.

This research was further supported by a Seed-financing DEEP-tech grant from the Austria Wirtschaftsservice (AWS) to Tridem Bioscience.